Lonza
Lonza
Revolutionary Cancer Treatment: Lonza and Qurient Unite!
🌟 Lonza's Synaffix and Qurient Therapeutics unite for dual-payload ADCs, enhancing cancer treatment with innovative cytotoxic agents! 💊🔬🚀
Lonza and RION Join Forces for Exosome Breakthrough!
🌟 Exciting collaboration! Lonza and RION are set to enhance exosome-based therapeutics manufacturing for innovative, affordable global treatments. 🌍💊🔬
Lonza Partners with CMAC for Advanced Drug Manufacturing
🌟 Lonza joins CMAC in Glasgow! This partnership boosts particle technology and enhances drug manufacturing efficiency. 🤝💊 PharmaInnovation ContinuousManufacturing
Revolutionary Needle-Free mRNA Vaccines for Flu!
🌟 Ethris and Lonza team up for room-temperature stable, spray-dried mRNA vaccines targeting respiratory diseases. 💉 Needle-free, efficient distribution! 🌍🚀
Exogenus and Lonza Team Up for Groundbreaking Therapy!
🌟 Exogenus Therapeutics partners with Lonza for GMP-compliant Exo-101 process. Promising treatment for tissue regeneration and inflammation! 🔬🤝
Revolutionary Nasal Treatments: Iconovo and Lonza Team Up!
🌟 Exciting news! Iconovo and Lonza join forces to develop innovative intranasal biologics for patient-friendly therapies. 🤝💡📉
Lonza Boosts Smart Capsules for Oral Drug Delivery!
Lonza expands smart capsule services for oral biologic drugs! 💊 Targeted delivery with advanced tech enhances patient care. 📈🌍🔧 HealthcareInnovation
Lonza Launches First GMP Batch at New Facility!
🌟 Lonza's first GMP batch at its new Portsmouth facility marks a leap in biomanufacturing, supporting innovative therapies! 💊🚀🔧
Lonza Doubles Capacity Adds 200 Jobs in Switzerland!
Lonza expands its Visp facility with two new bioconjugation suites, creating 200 jobs and doubling capacity for antibody-drug conjugates! 🌍🏗️💼📈🌱
Lonza Boosts US Manufacturing with $12B Acquisition!
🚀 Lonza has acquired Roche's Vacaville site for $1.2 billion, boosting U.S. manufacturing and investing $591 million for upgrades! 🏭✨
